Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026
ACCESSWIRE•27/10/2026•07:00 ET
0
Key Highlights
- ➤Protagonist (PTGX) to participate in four investment bank conferences in November 2026
- ➤ICOTYDE launched in U.S. in March 2026 for moderate-to-severe plaque psoriasis
- ➤ICOTYDE in Phase 3 development for psoriatic arthritis, ulcerative colitis and Crohn's disease
- ➤MIMRYLO approved in U.S. for erythrocytosis in adults with PV
NEWARK, CA / ACCESS Newswire / October 27, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that senior management will participate in four investment bank conferences taking place in November 2026.
8(th) Annual Wolfe Research Healthcare Conference Format: Fireside Chat and 1x1 meetings Date: Tuesday, November 10, 2026 Time: 1:20 - 1:50 p.m. EST Location: New York, NY
Get started
Create a free account to read the full story.